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Sex Med 2Introduction: Premature ejaculation (PE) is deﬁned as ejaculation within 1 minute (lifelong PE) or 3 minutes
(acquired PE), inability to delay ejaculation, and negative personal consequences. Management includes
behavioral and pharmacologic approaches.
Aim: To systematically review effectiveness, safety, and robustness of evidence for complementary and alternative
medicine in managing PE.
Methods: Nine databases including Medline were searched through September 2015. Randomized controlled
trials evaluating complementary and alternative medicine for PE were included.
Main Outcome Measures: Studies were included if they reported on intravaginal ejaculatory latency time
(IELT) and/or another validated PE measurement. Adverse effects were summarized.
Results: Ten randomized controlled trials were included. Two assessed acupuncture, ﬁve assessed Chinese herbal
medicine, one assessed Ayurvedic herbal medicine, and two assessed topical “severance secret” cream. Risk of bias
was unclear in all studies because of unclear allocation concealment or blinding, and only ﬁve studies reported
stopwatch-measured IELT. Acupuncture slightly increased IELT over placebo in one study (mean difference
[MD]¼ 0.55minute, P¼ .001). In another study, Ayurvedic herbal medicine slightly increased IELT over placebo
(MD ¼ 0.80 minute, P ¼ .001). Topical severance secret cream increased IELT over placebo in two studies
(MD ¼ 8.60 minutes, P < .001), although inclusion criteria were broad (IELT < 3 minutes). Three studies
comparingChinese herbalmedicinewith selective serotonin reuptake inhibitors (SSRIs) favored SSRIs (MD¼ 1.01
minutes, P¼ .02). However, combination treatment with Chinese medicine plus SSRIs improved IELT over SSRIs
alone (two studies; MD¼ 1.92 minutes, P< .00001) and over Chinese medicine alone (two studies; MD¼ 2.52
minutes, P < .00001). Adverse effects were not consistently assessed but where reported were generally mild.
Conclusion: There is preliminary evidence for the effectiveness of acupuncture, Chinese herbal medicine,
Ayurvedic herbal medicine, and topical severance secret cream in improving IELT and other outcomes. However,
results are based on clinically heterogeneous studies of unclear quality. There are sparse data on adverse effects or
potential for drug interactions. Further well-conducted randomized controlled trials would be valuable. Cooper
K, Martyn-St James M, Kaltenhaler E, et al. Complementary and Alternative Medicine for Management of
Premature Ejaculation: A Systematic Review. Sex Med 2017;5:e1ee18.Copyright  2016, The Authors. Published by Elsevier Inc. on behalf of the International Society for Sexual Medicine.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Premature ejaculation (PE) in men is characterized by short
ejaculatory latency during intercourse. PE can be lifelong (primary;
present since ﬁrst sexual experiences) or acquired (secondary;
beginning later).1 The International Society for Sexual Medicine
(ISSM; 2014) deﬁnes PE as a combination of (i) ejaculation usually
occurring within approximately 1 minute of vaginal penetration
(for lifelong PE) or a clinically signiﬁcant decrease in latency time,
often to no longer than approximately 3minutes (for acquired PE);e1
e2 Cooper et al(ii) inability to delay ejaculation; and (iii) negative personal con-
sequences such as distress, bother, frustration, and/or avoidance of
sexual intimacy.1 PE also has been deﬁned by the Diagnostic and
Statistical Manual of Mental Disorders, Fifth Edition (2013) as
ejaculation usually occurring within approximately 1 minute of
vaginal penetration and before the individual wishes it and causing
clinically signiﬁcant distress.2 Estimating the prevalence of PE is
not straightforward because of the difﬁculty in deﬁning what
constitutes clinically relevant PE. Surveys have estimated the
prevalence of self-reported early ejaculation as 20% to 30%3e5;
however, these estimates are likely to include men who have some
concern about their ejaculatory function but do not meet the
current diagnostic criteria for PE.6 It has been suggested that the
prevalence of lifelong PE according to the ISSM and theDiagnostic
and StatisticalManual ofMental Disorders, Fifth Edition deﬁnitions
(with an ejaculatory latency of approximately 1 minute) is unlikely
to exceed 4%.6 Men with PE are more likely to report lower levels
of sexual functioning and satisfaction and higher levels of personal
distress and interpersonal difﬁculty than men without PE.7 They
also might rate their overall quality of life as lower than that of men
without PE.7 In addition, their partner’s satisfaction with the
sexual relationship has been reported to decrease with increasing
severity of the condition.8
Management of PE can involve a range of interventions. These
include systemic drug treatments such as selective serotonin reup-
take inhibitors (SSRIs), tricyclic antidepressants, phosphodiesterase
type 5 inhibitors, and analgesics and topical anesthetic creams and
sprays that are applied directly to the penis shortly before inter-
course.9,10 Behavioral therapies also can be useful.6,9,11,12 These can
include psychosexual or relationship counseling for men and/or
couples to address psychological and interpersonal issues that could
be contributing to PE. Behavioral therapies also can include
physical techniques to help men develop sexual skills to delay
ejaculation and improve sexual self-conﬁdence, such as the “stop-
start” technique, “squeeze” technique, and sensate focus.6,9,11,12
There are sparse data on whether and for how long effectiveness is
maintained after cessation of treatment (drug or behavioral) and
whether repeat treatments are effective.
Many interventions currently used for PE are not approved for
this use, and men might choose to self-treat, with several
remedies being available through the internet. Some comple-
mentary and alternative medicines (CAMs) have been evaluated
in randomized controlled trials (RCTs) for the management of
PE. However, there are no existing systematic reviews evaluating
CAMs for management of PE. Our aim was to systematically
review the effectiveness, safety, and robustness of evidence for
CAM therapies in the management of PE.METHODS
Review Methods
This work was undertaken as part of a systematic review for the
UK National Institute for Health Research Health TechnologyAssessment Programme, which assessed a wide range of interventions
for management of PE.13 The review followed the general principles
recommended in the Preferred Reporting Items for Systematic Re-
views andMeta-Analyses (PRISMA) statement (http://www.prisma-
statement.org/).14 The review protocol is available from the Health
Technology Assessment Programme website (http://www.nets.nihr.
ac.uk/projects/hta/131201) and is registered on the PROSPERO
database (registration number CRD42013005289). The PRISMA
checklist is provided in Supplementary Appendix 3.Deﬁnition of CAM
CAM has been deﬁned by the Cochrane Collaboration as “a
broad domain of healing resources that encompasses all health
systems, modalities, and practices and their accompanying the-
ories and beliefs, other than those intrinsic to the politically
dominant health system of a particular society or culture in a
given historical period.”15 In addition, many CAM therapies are
based on a traditional model of health and well-being, and many
(although not all) are designed to treat the whole patient as
opposed to a speciﬁc condition, whereas some (although not all)
involve the use of traditional or natural therapies. Therefore,
CAM is deﬁned in this study as therapies for PE that have
typically not been provided within conventional Western health
care systems and that appear on the list of CAM therapies
collated by the Cochrane Collaboration.15Literature Searches
The following databases were searched from inception to
September 2015: Medline; Embase; Cumulative Index to Nursing
and Allied Health Literature (CINAHL); the Cochrane Library
including the Cochrane Systematic Reviews Database (CDSR), the
Cochrane Controlled Trials Register (CCRT), the Database of
Abstracts of Reviews of Effects (DARE), and the Health Technol-
ogy Assessment database; the ISI Web of Science including the
Science Citation Index and the Conference Proceedings Citation
IndexeScience. The Medline search strategy is provided in
Appendix 1.The search strategywas designed to identify any articles
tagged with the Medical Subject Headings ejaculation or premature
ejaculation plus articles whose title or abstract included one of the
terms premature, early, or rapid within three words of ejaculation or
climax or the term ejaculation praecox/precox. These were combined
with search ﬁlters to identify RCTs, reviews, and guidelines. It
should be noted that the search was undertaken as part of a wider
project assessing different treatments for PE,13 and for this reason
the search was not speciﬁc to complementary therapies. The US
Food and Drug Administration website and the European
Medicines Agency website also were searched. Existing systematic
reviews and relevant studies also were checked for eligible studies.Eligibility Criteria
RCTs were eligible for inclusion if they compared CAM
therapies for management of PE against placebo, waitlist, no
treatment, or another therapy or assessed combination treatment.Sex Med 2017;5:e1ee18
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Studies were included if they reported intravaginal ejaculatory
latency time (IELT) and/or any of the following PE outcome
measurements:
- Premature Ejaculation Proﬁle (PEP)16
- Index of Premature Ejaculation (IPE)17
- Premature Ejaculation Diagnostic Tool (PEDT)18
- Arabic Index of Premature Ejaculation (AIPE)19
- Chinese Index of Premature Ejaculatione5 (CIPE-5)20
- International Index of Erectile Function (IIEF)21
Five of these measurements (PEP, IPE, PEDT, AIPE, and
CIPE) were referenced in the update of the ISSM PE guidelines.6
Of these, PEP and IPE have been validated as tools to measure
changes in PEoutcomes,16,17 andCIPE also has been evaluated as a
PE outcome measurement.20 The PEDT and AIPE have been
validated as tools for diagnosing PE18,19 and have been used as
outcome measurements in PE trials. In addition, the IIEF was
validated for measuring changes in outcomes in erectile dysfunc-
tion, but some dimensions overlap with PE and have been used to
measure outcomes in PE studies.21 Adverse effects also were
summarized. Poorly deﬁned outcomes, such as “percentage of
patients showing improvement,” were not included in this review.Data Extraction and Synthesis
One reviewer performed data extraction of each study; all
numerical data were checked by a second reviewer. Results were
presented as forest plots where data permitted, and meta-analyses
were undertaken using RevMan software.22 Assessment of pub-
lication bias by visual inspection of funnel plots was planned
when at least 10 RCT comparisons were available.23Assessment of Methodologic Quality of Studies
Methodologic quality of included RCTs was assessed using the
Cochrane Collaboration risk-of-bias assessment criteria.24
Completeness of outcome data was considered low risk if the per-
centage of randomized participants excluded from the primary
analysis was smaller than 30%.25 Selective reporting was considered
low risk if IELT or ejaculatory latency was reported and all out-
comes referred to in the study methods were reported. Overall risk
of bias for each studywas classed as “low” or “high” if theywere rated
as such for each of three key domains: allocation concealment,
blinding of outcome assessment, and completeness of outcome
data; otherwise, overall risk of bias was classed as “unclear.”RESULTS
Quantity of Evidence
The searches identiﬁed 2,455 citations (as part of a wider
project assessing different treatments for PE). Fourteen studiesSex Med 2017;5:e1ee18were examined at the full-text stage. Ten RCTs evaluating a
complementary therapy for PE were included in the review.26e35
The PRISMA ﬂowchart is presented in Appendix 2. The four
studies excluded at the full-text stage are described below, with
reasons for exclusion.Characteristics of Included Studies
Details of the included study characteristics are presented in
Table 1; details include speciﬁc acupuncture points and herbal
remedies used. Two studies (one in Turkey26 and one in
China27) assessed acupuncture provided daily for 4 weeks and
twice weekly for 4 weeks, respectively. Each study used a set
range of acupuncture points (with some overlap but some dif-
ferences between studies). Five studies assessed a 2- to 8-week
course of oral Chinese herbal medicine; all were conducted in
China.28e32 One study conducted in India assessed Ayurvedic
medicine (Indian herbal medicine) given for 2 months.33 Two
Korean studies assessed four to ﬁve treatments with “severance
secret” (SS) cream,34,35 an extract of nine natural products that is
applied to the penis 1 hour before intercourse and washed off
before intercourse. SS cream is believed to work by localized
desensitizing effects to decrease penile hypersensitivity.34
The number of analyzed participants was 50 to 200 for all
studies, with the mean and median numbers being 98. Com-
parators included placebo (four studies),26,33e35 treatment as
usual (one study),32 an SSRI (ﬁve studies),26e29,31 and/or a
combination of CAM and drug treatment (three studies).28,30,31
Nine of the 10 studies assessed IELT26,28e35: ﬁve by stop-
watch,26,28,29,34,35 one by questionnaire,32 and three did not
report the method of IELT assessment.30,31,33 Additional
outcome measurements reported included the PEDT (three
studies)26,28,29, the CIPE-5 (two studies)27,32, and the IIEF (one
study).31
Three studies included men with lifelong PE,30,34,35 one
included men with only acquired PE,28 four included men with
lifelong PE and men with acquired PE,26,29,32,33 and two did not
report this information.27,31 Participants had an IELT no longer
than 1 minute (most or all the time) in two studies,28,33 an IELT
no longer than 2 minutes (most or all the time) in ﬁve stud-
ies,26,29e32 an IELT no longer than 3 minutes in two
studies,34,35 and IELT inclusion criteria were not reported in one
study.27 In four studies, patient or partner satisfaction also had to
be below 30% or below 50%.32e35 In some studies, the inclu-
sion criteria were not consistent with the ISSM deﬁnition of PE.
For example, one study of Chinese herbal medicine recruited
men with acquired PE, but they had to have an IELT shorter
than 1 minute in at least 50% of attempts28 (whereas the ISSM
widens the deﬁnition of acquired PE to IELT  3 minutes36).
Also, two studies of SS cream stated that participants had lifelong
PE but were required only to have an IELT shorter than 3
minutes (plus patient or partner satisfaction below 30% or
50%)34,35 rather than no longer than 1 minute according to the
ISSM deﬁnition of lifelong PE.6
Table 1. Characteristics of included studies
Study; country;
center, n Duration (n), IELT assessment Treatments and comparators CAM treatment details PE deﬁnition
Lifelong and
acquired
Acupuncture
Sunay et al,26
2011; Turkey; 1
4 wk (n ¼ 90, a ¼ 90),
stopwatch
Acupuncture 2/wk; paroxetine
20 mg/d; sham acupuncture
2 weekly
Acupuncture 2/wk using points
Zusanli (ST 36), Hegu (LI 4),
Taixi (KI 3), Taichong (LR 3),
Yintang (EX-HN 3), Zhongji
(CV 3)
IELT  2 min in >70%
of attempts
Lifelong 66%,
acquired 34%
Chen,27 2009;
China; 1
4 wk (n ¼ 111, a ¼ 111),
method NR
Acupuncture daily;
citalopram 20 mg/d
Acupuncture: 2 groups of acupoints
on alternate days: day 1, Xinshu
(BL 15), Ganshu (BL 18), Pishu
(BL 20), Shenshu (BL 23); day 2,
Guanyuan (CV 4), Zhongji (CV 3),
Sanyinjiao (SP 6), Taixi (KI 3),
Taichong (LR 3)
NR NR
Chinese herbal
medicine
Li and Lu,28
2015; China; 1
4 wk (n ¼ 120, a ¼ 119),
stopwatch
Chinese medicine (Qilin pills)
6 g 2/d; sertraline 50 mg/d;
Chinese medicine þ sertraline
Chinese medicine (Qilin pills)
containing Chinese raspberry
(fu pen zi), horny goat weed
(yin yang huo), Polygonum
multiﬂorum (he shou wu), Herba
ecliptae (mo han lian),
Cynomonium (suo yang),
Astralagus (huang qi), Chinese
yam (shan yao), immature
tangerine peel (qing pi), mulberry
fruit spike (sang shen), turmeric
tuber (yu jin), Chinese red sage
(dan shen), white peony root
(bai shao)
IELT < 1 min in >50%
of attempts þ TCM
deﬁnition of “secondary
non-consolidated kidney
qi PE”
Acquired (3 mo)
Xu et al,29
2014; China; 1
8 wk (n ¼ 218, a ¼ 200),
stopwatch
Chinese medicine (mycelium
of Cordyceps sinensis C4);
sertraline 50 mg/d
Chinese medicine (mycelium of
Cordyceps sinensis C4)
IELT  2 min in 75%
of attempts
Acquired and
lifelong (n ¼ NR)
Xu et al,30
2012; China; 1
4 wk (n ¼ 68, a ¼ 68),
method NR
Chinese medicine (Yimusake
50 mg/d); Chinese medicine þ
trazodone 50 mg/d
Chinese medicine (Yimusake
50 mg/d)
IELT < 2 min Lifelong
Sun et al,31
2010; China; 2
4 wk (n ¼ 114, a ¼ 114),
method NR
Chinese medicine (Yimusake
1.5 g/d); ﬂuoxetine 20 mg/d;
Chinese medicine þ ﬂuoxetine
Chinese medicine (Yimusake
1.5 g/d)
IELT < 2 min NR
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Table 1. Continued
Study; country;
center, n Duration (n), IELT assessment Treatments and comparators CAM treatment details PE deﬁnition
Lifelong and
acquired
Song et al,32
2007; China; 2
15 d (n ¼ 68, a ¼ 68),
questionnaire
Chinese medicine (Uighur) 2/d;
treatment as usual
Chinese medicine (Uighur) 2/d IELT  2 min, partner
satisfaction < 50%
Acquired and
lifelong (n ¼ NR)
Ayurvedic herbal
medicine
Kulkarni and
Chandola,33
2013; India; 1
2 mo (n ¼ 55, a ¼ 50),
method NR
Ayurvedic herbal medicine
2/d þ psychological
counseling; placebo þ
psychological counseling
Ayurvedic herbal medicine 2/d:
Stambhanakaraka Yoga
containing Tulsi beeja (Occimum
santum Linn), Akarakarabha
(Anacyclus pyrethrum Linn), Mishri
(sugar)
IELT  1 min, partner
satisfaction < 50%
Acquired and
lifelong (n ¼ NR)
Topical herbal
SS cream
Choi et al,34
2000; Korea;
3 (crossover)
5 applications (n ¼ 125,
a ¼ 106), stopwatch
SS cream (0.20 g applied
1 h before intercourse);
placebo
SS cream: extracts of 9 natural
products applied to glans penis 1 h
before intercourse and then
washed off (Ginseng radix alba,
Angelicae gigantis radix,
Cistanches herba, Zanthoxyli
fructus, Torlidis semen, Asiasari
radix, Caryophylli ﬂos, Cinnamomi
cortex, Bufonis venenum)
IELT < 3 min AND
patient and partner
satisfaction <30%
Lifelong
Choi et al,35
1999; Korea;
1 (crossover)
4 applications (1 of
each dose; n ¼ 73,
a ¼ 50), stopwatch
SS cream (0.05, 0.10, 0.15,
or 0.20 g applied 1 h before
intercourse); placebo
SS cream: extracts of 9 natural
products as above
IELT < 3 min and/or
patient satisfaction
< 50%
Lifelong
a ¼ analyzed number; CAM ¼ complementary and alternative medicine; IELT ¼ intravaginal ejaculatory latency time; n ¼ randomized number; NR ¼ not reported; PE ¼ premature ejaculation; SS ¼ secret
severance; TCM ¼ traditional Chinese medicine.
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Table 2. Risk of bias in included studies
RCT; country
Risk of bias
Random
sequence
generation
Allocation
concealment
Blinding of
participants
and personnel
Blinding of
outcome
assessment
Completeness
of outcome data*
(n/N, % included
in primary analysis)
Selective
reporting†
Overall
risk‡
Acupuncture
Sunay et al,26
2011; Turkey
Low Unclear Low (partial
blinding)
Unclear Low (90/90, 100%) Low Unclear
Chen,27 2009;
China
Unclear Unclear High Unclear Low (111/111, 100%) High (no IELT) Unclear
Chinese herbal
medicine
Li and Lu,28
2015; China
Low Unclear High Unclear Low (119/120, 99%) Low Unclear
Xu et al,29
2014; China
Low Unclear Low Unclear Low (200/218, 92%) Low Unclear
Xu et al,30
2012; China
Unclear Unclear High Unclear Low (68/68, 100%) Low Unclear
Sun et al,31
2010; China
Unclear Unclear High Unclear Low (114/114, 100%) Low Unclear
Song et al,32
2007; China
Low Unclear High Unclear Low (68/68, 100%) Low Unclear
Ayurvedic herbal
medicine
Kulkarni and
Chandola,33
2013; India
Unclear Unclear Low Unclear Low (50/55, 91%) Low Unclear
Topical herbal
SS cream
Choi et al,34
2000; Korea
Unclear Unclear Low Unclear Low (106/125, 85%) Low Unclear
Choi et al,35
1999; Korea
Low Unclear Low Low High (50/73, 68%) Low Unclear
IELT ¼ intravaginal ejaculatory latency time; SS ¼ secret severance.
*Completeness of outcome data was classed as low risk if fewer than 30% randomized participants were excluded from the primary analysis.
†Selective reporting was classiﬁed as low risk if IELT or ejaculatory latency was reported and all outcomes referred to in study methods were reported.
‡Overall risk of bias was classiﬁed as low or high if rated as such for each of three key domains: allocation concealment, blinding of outcome assessment, and
completeness of outcome data; otherwise, overall risk of bias was classed as unclear.
e6 Cooper et alStudies Excluded at Full-Text Stage
Four studies were excluded at the full-text stage. Two studies
of Chinese medicine were excluded because they did not report
on IELT or any validated or widely used PE outcome mea-
surement.36,37 Two studies assessing a combination of yoga and
pelvic ﬂoor exercises were excluded; one was not randomized
(patients self-selected to the intervention or control group)38 and
the other did not report on IELT or any validated or widely used
PE outcome measurement.39Risk of Bias in Included Studies
The risk of bias within included studies is presented in Table 2.
Five studies reported the method of randomization,26,28,29,32,35
whereas the other ﬁve did not report the method but did state
that the study was randomized. Allocation concealment wasunclear in all studies. Blinding of participants and personnel was
reported as being undertaken in ﬁve studies.26,29,33e35 Blinding of
outcome assessment was unclear in all studies except one,35 which
reported that this was blinded. All studies except one35 were
considered at low risk of bias for completeness of outcome data,
with eight studies including at least 90% of randomized patients in
the primary analysis and the two studies of SS cream including
85%34 and 68%,35 respectively. All studies scored a low risk for
selective reporting except for one that did not report on IELT.27Of
the nine studies reporting on IELT, this was measured by stop-
watch in ﬁve studies,26,28,29,34,35 by questionnaire in one study,32
and the method of IELT assessment was not reported in three
studies.30,31,33 In summary, all 10 studies were classed as having an
overall unclear risk of bias because of unclear reporting of allocation
concealment (all 10 studies) and unclear blinding of participants
and personnel (ﬁve studies).Sex Med 2017;5:e1ee18
Table 3. Effectiveness results
Studies, n Treatment Comparator Duration Reference Outcome
Participants,
n MD (95% CI), P value Favors
Acu vs placebo
1 Acu 2x/wk Sham acu 4 wk Sunay 201126 IELT (stopwatch)
PEDT
60
60
MD ¼ 0.55 (NR), .001
MD ¼ NR (NR), .001
Acu over sham
Acu over sham
Acu vs drug
2 Acu 2x/wk Paroxetine
20 mg/d
4 wk Sunay 201126 IELT (stopwatch)
PEDT
60
60
MD ¼ 0.28 (NR), .001
MD ¼ NR (NR), NS
Drug over acu
Not sig (acu
vs drug)
Acu daily Citalopram
20 mg/d
4 wk Chen 200927 CIPE-5 111 MD ¼ 1.44 (0.02 to
2.86), .05
Acu over drug
CM vs TAU
1 CM (Uighur 2x/d) TAU 15 d Song 200732 IELT (questionnaire)
CIPE-5
68
68
MD ¼ 1.57 (1.11 to 2.03),
.00001
MD ¼ 4.95 (3.34 to
6.56), .00001
CM over TAU
CM over TAU
CM vs drug
3 CM (Qilin pills
6 g 2x/d)
Sertraline
50 mg/d
4 wk Li 201528 IELT (stopwatch)
PEDT
79
79
MD ¼ 0.64 (1.58 to
0.30), .18
MD ¼ 0.20 (0.97 to
0.57), .61
Not sig (drug
vs CM)
Not sig (drug
vs CM)
CM (mycelium of
cordyceps
sinensis C4)
Sertraline
50 mg/d
8 wk Xu 201429 IELT (stopwatch)
PEDT
200
200
MD ¼ 1.70 (2.12 to
1.28), <.01
MD ¼ 3.8 (5.01 to
2.59), <.01
Drug over CM
Drug over CM
CM (Yimusake
1.5 g/d)
Fluoxetine
20 mg/d
4 wk Sun 201031 IELT (method NR)
Satisfaction (IIEF)
76
76
MD ¼ 0.60 (1.01 to
0.19), .004
MD ¼ 0.90 (1.43 to
0.37), .0009
Drug over CM
Drug over CM
CM + drug vs drug alone
2 CM (Qilin) þ
sertraline
Sertraline
50 mg/d
4 wk Li 201528 IELT (stopwatch)
PEDT
79
79
MD ¼ 2.05 (0.83 to
3.27), .001
MD ¼ 1.10 (0.46 to
1.74), .0008
Combined over
drug
Combined over
drug
CM (Yimusake) þ
ﬂuoxetine
Fluoxetine
20 mg/d
4 wk Sun 201031 IELT (method NR)
Satisfaction (IIEF)
76
76
MD ¼ 1.90 (1.47 to
2.33), <.00001
MD ¼ 3.00 (2.46 to
3.54), <.00001
Combined over
drug
Combined over
drug
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Table 3. Continued
Studies, n Treatment Comparator Duration Reference Outcome
Participants,
n MD (95% CI), P value Favors
CM þ drug vs CM alone
3 CM (Qilin) þ
sertraline
CM (Qilin
6 g 2x/d)
4 wk Li 201528 IELT (stopwatch)
PEDT
80
80
MD ¼ 2.69 (1.57 to
3.81), <.00001
MD ¼ 1.30 (0.63 to
1.97), .0001
Combined over CM
Combined over CM
CM (Yimusake) þ
ﬂuoxetine
CM (Yimusake 1.5
g/d)
4 wk Sun 201031 IELT (method NR)
Satisfaction (IIEF)
76
76
MD ¼ 2.50 (2.08 to
2.92), <.00001
MD ¼ 3.90 (3.32 to
4.48), <.00001
Combined over CM
Combined over CM
CM (Yimusake
50 mg/d) þ
trazodone 50 mg/d
CM (Yimusake 50
mg/d)
4 wk Xu 201230 IELT (method NR) 68 MD ¼ 0.08 (0.19 to
0.35), .56
Not sig (combined
vs. CM)
Ayurvedic herbal medicine vs placebo
1 Ayurvedic med þ
counselling
Placebo +
counselling
2 mo Kulkarni 201333 IELT (method NR) 50 MD ¼ 0.80 (0.32 to
1.28), .001
Ayurveda þ
counselling over
placebo þ
counselling
Topical herbal SS cream vs placebo
2 SS cream
(0.2 g/h prior)
Placebo
(crossover)
5 app Choi 200034 IELT (stopwatch) 106 MD ¼ 8.47 (6.52 to
10.42), <.001
SS cream over
placebo
SS cream
(0.2 g/h prior)
Placebo
(crossover)
1 app Choi 199935 IELT (stopwatch) 50 MD ¼ 8.79 (6.41 to
11.17), <.001
SS cream over
placebo
Acu ¼ acupuncture; app ¼ applications; CI ¼ conﬁdence interval; CIPE ¼ Chinese Index of Premature Ejaculation; CM ¼ Chinese medicine; IELT ¼ intra-vaginal ejaculatory latency time; IIEF ¼ International
Index of Erectile Function; MD ¼ mean difference; NR ¼ not reported; PEDT ¼ Premature Ejaculation Diagnostic Tool; TAU ¼ treatment as usual.
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Table 4. Adverse effects
Study, country, duration (n) Treatments AEs
Acupuncture
Sunay et al,26 2011, Turkey, 4 wk
(n ¼ 90, a ¼ 90)
Acupuncture 2/wk, paroxetine 20 mg/d,
sham acupuncture 2/wk
No AEs observed (although no formal
evaluation of AEs)
Chen,27 2009, China, 4 wk (n ¼ 111,
a ¼ 111)
Acupuncture daily, citalopram 20 mg/d NR
Chinese herbal medicine
Li and Lu,28 2015, China, 4 wk
(n ¼ 120, a ¼ 119)
CM (Qilin pills 6 g 2/d), sertraline
50 mg/d, CM þ sertraline
CM: no AEs reported
Sertraline: mild transient AEs
(gastrointestinal discomfort in 3,
headache and dizziness in 2); 1 patient
receiving only sertraline discontinued
because of erectile dysfunction
Xu et al,29 2014, China, 8 wk
(n ¼ 218, a ¼ 200)
CM (mycelium of Cordyceps sinensis C4),
sertraline 50 mg/d
CM: 7/61 (11.5%) developed mild AEs
(dizziness in 2, decreased libido in 1,
gastrointestinal discomfort in 4), no
discontinuations
Sertraline: 52/157 (33.1) developed mild
AEs (dizziness in 30, decreased libido
in 12, other); 3/157 (1.9%) discontinued
because of severe dizziness
Xu et al,30 2012, China, 4 wk
(n ¼ 68, a ¼ 68)
CM (Yimusake 50 mg/d), CM þ trazodone
50 mg/d
CM alone: no AEs
CM þ trazodone: minor AEs (headache in
2, dry mouth in 1, constipation in 1)
Sun et al,31 2010, China, 4 wk
(n ¼ 114, a ¼ 114)
CM (Yimusake 1.5 g/d), ﬂuoxetine
20 mg/d, CM þ ﬂuoxetine
Number of AEs with CM þ ﬂuoxetine
were not signiﬁcantly different from
CM or ﬂuoxetine alone (included
nausea, dizziness, headache, ﬂushing,
somnolence)
Song et al,32 2007, China, 15 d
(n ¼ 68, a ¼ 68)
CM (Uighur) 2/d, treatment as usual NR
Ayurvedic herbal medicine
Kulkarni and Chandola,33 2013, India,
2 mo (n ¼ 55, a ¼ 50)
Ayurvedic medicine þ counseling,
placebo þ counseling
NR
Topical herbal SS cream
Choi et al,34 2000, Korea, 6
applications (n ¼ 125, a ¼ 106)
SS cream (0.20 g 1 h before intercourse),
placebo
SS cream: mild burning sensation in 15%
of applications, mild pain in 4% of
applications, effects resolved < 1 h
Choi et al,35 1999, Korea, 4
applications (n ¼ 73, a ¼ 50)
SS cream (0.05, 0.10, 0.15 or 0.20 g
1 h before intercourse), placebo
SS cream: mild burning sensation in 15%
of applications, mild pain in 0.04% of
applications
a ¼ number analyzed; AE ¼ adverse effect; CM ¼ Chinese medicine; n ¼ number randomized; NR ¼ not reported; SS ¼ secret severance.
CAM for Management of Premature Ejaculation e9Assessment of Effectiveness and Safety
Effectiveness results are presented in Table 3 and adverse
effects are presented in Table 4. Further details of effectiveness
(including results data per study group) are presented in Table 5.
Acupuncture
Two RCTs (one in Turkey26 and one in China27) assessed
acupuncture provided daily for 4 weeks and twice weekly for 4
weeks, respectively. Each study used a standardized range of
acupuncture points for all patients. There was some overlap,
but also some differences, between the acupuncture points
used in the two studies (Table 1). There were no studies ofSex Med 2017;5:e1ee18individualized acupuncture treatment (where different points are
used per patient based on clinical examination).
One study compared acupuncture against sham acupuncture
(N analyzed ¼ 60) and reported a small but signiﬁcant
improvement in stopwatch-measured IELT for acupuncture over
sham (mean difference (MD) ¼ 0.55 minute, P ¼ .001) and a
signiﬁcant improvement in PEDT score (P ¼ .001; Table 3).26
These two studies showed mixed results when comparing
acupuncture against drug treatment with an SSRI (paroxetine or
citalopram, each given daily for 4 weeks),26,27 with IELT
favoring drug treatment in the one study reporting this (N ¼ 60;
MD ¼ 0.28, P ¼ .001),26 a PEDT score showing no
Table 5. Effectiveness results including results per group
Study, country Treatment Comparator Duration Outcome
Participants
analyzed, n
Results per group,
mean (SD)
MD (95% CI),
P value Favors
Acupuncture vs
placebo
Sunay et al,26
2011, Turkey
Acu 2/wk Sham acu 4 wk IELT (stopwatch)
PEDT
60 acu: 1.10 (NR), sham
acu: 0.55 (NR)†
acu: 4.0, sham
acu: 0.0‡
0.55 (NR), .001
NR (NR), .001
Acu over sham
Acu over sham
Acupuncture vs
drug
Sunay et al,26
2011, Turkey
Acu 2/wk Paroxetine
20 mg/d
4 wk IELT (stopwatch)
PEDT
60 acu: 1.10 (NR),
paroxetine: 1.38
(NR)†
acu: 4.0,
paroxetine: 5.0‡
0.28 (NR), .001
NR (NR), NS
Drug over acu
Acu vs drug NS
Chen,27 2009,
China
Acu daily Citalopram
20 mg/d
4 wk CIPE-5 111 acu: 12.56 (3.84),
citalopram: 11.12
(3.77)*
1.44 (0.02e2.86),
.05
Acu over drug
CM vs TAU
Song et al,32
2007, China
CM (Uighur 2/d) TAU 15 d IELT (questionnaire)
CIPE-5
68 CM: 2.73 (1.25),
TAU: 1.16 (0.58)*
CM: 15.80 (3.60),
TAU: 10.85 (3.18)*
1.57 (1.11e2.03),
<.00001
4.95 (3.34e6.56),
<.00001
CM over TAU
CM over TAU
CM vs drug
Li and Lu,28
2015, China
CM (Qilin pills 6 g
2/d)
Sertraline
50 mg/d
4 wk IELT (stopwatch)
PEDT
79 CM: 3.23 (1.84),
sertraline: 3.87
(2.43)*
CM: 5.1 (1.8),
sertraline: 4.9
(1.7)*
0.64 (1.58 to
0.30), .18
0.20 (0.97 to
0.57), .61
CM vs drug NS
CM vs drug NS
Xu et al,29 2014,
China
CM (mycelium of
Cordyceps sinensis
C4)
Sertraline
50 mg/d
8 wk IELT (stopwatch)
PEDT
200 CM: 1.4 (0.7),
sertraline: 3.1
(2.3)*
CM: 14.8 (3.5),
sertraline: 11.0
(4.9)*
1.70 (2.12 to
1.28), <.01
3.8 (5.01 to
2.59), <.01
Drug over CM
Drug over CM
Sun et al,31
2010, China
CM (Yimusake
1.5 g/d)
Fluoxetine
20 mg/d
4 wk IELT (method NR)
satisfaction (IIEF)
76 CM: 5.2 (0.87),
ﬂuoxetine: 5.8
(0.94)*
CM: 10.3 (1.26),
ﬂuoxetine: 11.2
(1.09)*
0.60 (1.01 to
0.19), .004
0.90 (1.43 to
0.37), .0009
Drug over CM
Drug over CM
(continued)
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Table 5. Continued
Study, country Treatment Comparator Duration Outcome
Participants
analyzed, n
Results per group,
mean (SD)
MD (95% CI),
P value Favors
CM þ drug vs
drug alone
Li and Lu,28
2015, China
CM (Qilin pills) þ
sertraline 50 mg/d
Sertraline
50 mg/d
4 wk IELT (stopwatch)
PEDT
79 CM þ sertraline:
5.92 (3.11),
sertraline: 3.87
(2.43)*
CM þ sertraline: 3.8
(1.2), sertraline:
4.9 (1.7)*
2.05 (0.83e3.27),
.001
1.10 (0.46e1.74),
.0008
Combined over drug
Combined over drug
Sun et al,31
2010, China
CM (Yimusake) þ
ﬂuoxetine
20 mg/d
Fluoxetine
20 mg/d
4 wk IELT (method NR)
satisfaction (IIEF)
76 CM þ ﬂuoxetine: 7.7
(0.98), ﬂuoxetine:
5.8 (0.94)*
CM þ ﬂuoxetine:
14.2 (1.31),
ﬂuoxetine: 11.2
(1.09)*
1.90 (1.47e2.33),
<.00001
3.00 (2.46e3.54),
<.00001
Combined over drug
Combined over drug
CM þ drug vs
CM alone
Li and Lu,28
2015, China
CM (Qilin pills) þ
sertraline
50 mg/d
CM (Qilin pills) 4 wk IELT (stopwatch)
PEDT
80 CM þ sertraline:
5.92 (3.11), CM:
3.23 (1.84)*
CM þ sertraline: 3.8
(1.2), CM: 5.1 (1.8)*
2.69 (1.57e3.81),
<.00001
1.30 (0.63e1.97),
.0001
Combined over CM
Combined over CM
Sun et al,31
2010, China
CM (Yimusake) þ
ﬂuoxetine
20 mg/d
CM (Yimusake) 4 wk IELT (method NR)
satisfaction (IIEF)
76 CM þ ﬂuoxetine: 7.7
(0.98), CM 5.2
(0.87)*
CM þ ﬂuoxetine:
14.2 (1.31), CM:
10.3 (1.26)*
2.50 (2.08e2.92),
<.00001
3.90 (3.32e4.48),
<.00001
Combined over CM
Combined over CM
Xu et al,30
2012, China
CM (Yimusake) þ
trazodone
50 mg/d
CM (Yimusake) 4 wk IELT (method NR) 68 CM þ trazodone:
3.05 (0.60), CM:
2.97 (0.54)*
0.08 (0.19 to
0.35), .56
Combined vs CM NS
Ayurvedic herbal
medicine vs
placebo
Kulkarni and
Chandola,33
2013, India
Ayurvedic
medicine þ
counseling
Placebo þ
counseling
2 mo IELT (method NR) 50 Ayurveda: 1.85
(0.91), placebo:
1.05 (0.82)†
0.80 (0.32e1.28),
.001
Ayurveda þ
counseling
over placebo þ
counseling
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e12 Cooper et alsigniﬁcant difference (P value not reported),26 and a CIPE-5
score favoring acupuncture in the other study (N ¼ 111;
P ¼ .05).27 One study reported that no adverse effects were
observed (although there was no formal evaluation of these),26
and the other study did not report adverse effect data (Table 4).27
In summary, the available data indicate that acupuncture
might be slightly more effective than placebo (sham) in treating
PE, although this is based on only one study of unclear quality.Chinese Herbal Medicine
Five RCTs (all conducted in China) assessed a 2- to 8-week
course of oral Chinese herbal medicine.28e32 Each study used
the same herbal medicine(s) for all patients. There were no
studies of individualized Chinese medicine (where different herbs
are used per patient based on clinical examination). The speciﬁc
Chinese medicines used differed among studies. One study used
Qilin pills (a combination of herbs; Table 1) at a dose of 6 g
twice daily28; one used mycelium of Cordyceps sinensis C429; two
used Yimusake (one at 50 mg/d30 and one at 1.5 g/d31); and one
used Uighur twice daily.32
Results for Chinese medicine are presented in Table 3 and
Figures 1 and 2. One study favored Chinese medicine (Uighur)
over treatment as usual (N analyzed ¼ 68),32 reporting
signiﬁcant differences in IELT measured by questionnaire
(MD ¼ 1.57 minutes, 95% CI ¼ 1.11e2.03, P < .00001) and
CIPE-5 score (P < .00001; Table 3 and Figure 1). Three studies
compared Chinese medicine against drug treatment with an
SSRI (ﬂuoxetine or sertraline, each given daily for 4e8
weeks).28,29,31 Of these, two studies signiﬁcantly favored SSRIs
over Chinese medicine (mycelium of Cordyceps sinensis C4 or
Yimusake) for IELT (one measured by stopwatch) and PEDT
and IIEF scores,29,31 whereas the third study showed no signif-
icant difference in stopwatch-measured IELT or PEDT score
between the SSRI and Chinese medicine (Qilin pills; Table 3).28
A meta-analysis of IELT across all three studies signiﬁcantly
favored drug treatment with SSRIs (total N ¼ 355; pooled
MD ¼ 1.01 minutes, 95% CI ¼ 0.18e1.84, P ¼ .02; Figure 1),
with a high level of heterogeneity (I2 ¼ 86%, P ¼ .0007).
Two studies compared Chinese medicine (Qilin pills or
Yimusake) plus SSRI (ﬂuoxetine or sertraline) against SSRI
alone.28,31 These studies (total N ¼ 155) signiﬁcantly
favored combination treatment over SSRI alone for IELT
(one measured by stopwatch; pooled MD ¼ 1.92 minutes, 95%
CI ¼ 1.51e2.32, P < .00001) with low heterogeneity (I2 ¼ 0%,
P ¼ .82); PEDT and IIEF scores also favored combination
treatment (P < .001 for the two comparisons; Table 3 and
Figure 2).
The same two studies compared Chinese medicine (Qilin pills
or Yimusake) plus SSRI (ﬂuoxetine or sertraline) against Chinese
medicine alone.28,31 These studies (total N ¼ 156) signiﬁcantly
favored combination treatment over Chinese medicine alone for
IELT (one measured by stopwatch; pooled MD ¼ 2.52,Sex Med 2017;5:e1ee18
Figure 1. Intravaginal ejaculatory latency time for Chinese medicine (CM).
CAM for Management of Premature Ejaculation e1395% CI ¼ 2.13e2.91, P < .00001) with low heterogeneity
(I2 ¼ 0%, P ¼ .76); PEDT and IIEF scores also favored com-
bination treatment (P < .0001 for all comparisons). Results fa-
voring combination treatment over drug or Chinese medicine
alone (for IELT and PEDT) remained signiﬁcant 1 month after
treatment ended in the one study reporting this.28 A third study
(N ¼ 68) comparing Chinese medicine (Yimusake) plus a sero-
tonin antagonist and reuptake inhibitor (trazodone) against
Chinese medicine alone30 showed no signiﬁcant difference in
IELT (measurement method not reported; MD ¼ 0.08, 95%
CI ¼ 0.19 to 0.35, P ¼ .56; Table 3 and Figure 2).
Four of ﬁve studies reported data on adverse effects
(Table 4).28e31 For patients receiving Chinese medicine alone,
two studies reported that no adverse effects were observed (one of
Qilin pills 6 g twice daily28 and one of Yimusake 50 mg/d30).
One study reported adverse effects in 12% of patients receivingFigure 2. Intravaginal ejaculatory latency time for Chinesemedicine (CM
antagonist and reuptake inhibitor (trazodone); sert ¼ sertraline; SSRI ¼
Sex Med 2017;5:e1ee18mycelium of Cordyceps sinensis C4 (including gastrointestinal
discomfort, dizziness, and decreased libido),29 whereas one study
reported that the number of adverse effects did not differ
signiﬁcantly among Chinese medicine alone (Yimusake 1.5 g/d),
ﬂuoxetine alone, and combination treatment.31
In summary, across studies of Chinese medicine, one study
favored Chinese medicine over treatment as usual.32 A meta-
analysis of three studies favored SSRI treatment over Chinese
medicine.28,29,31 Two studies favored Chinese medicine plus
SSRIs over SSRIs alone or Chinese medicine alone.28,31Ayurvedic Medicine
One RCT conducted in India (N analyzed ¼ 50) assessed a
2-month course of Ayurvedic medicine (Indian herbal medicine)
plus psychological counseling compared with placebo plus) combinedwith drug treatment.ﬂuox¼ ﬂuoxetine; SARI¼ serotonin
selective serotonin reuptake inhibitor; trazo ¼ trazodone.
Figure 3. Intravaginal ejaculatory latency time for secret severance (SS) cream.
e14 Cooper et alpsychological counseling.33 Ayurvedic medicine showed a small
but signiﬁcant improvement in IELT (measurement method not
reported; MD ¼ 0.80 minute, 95% CI ¼ 0.32e1.28, P ¼ .001;
Table 3). Adverse effects were not reported.SS Cream
Two crossover RCTs conducted in Korea compared SS cream
against placebo.34,35 These two RCTs showed signiﬁcant
effects on stopwatch-measured IELT (total N ¼ 156; pooled
MD ¼ 8.60 minutes, 95% CI ¼ 7.09e10.10, P < .001) with
low heterogeneity (I2 ¼ 0%, P ¼ .84; Table 3 and Figure 3).
The two studies used a single-group crossover design in which
each patient received four or ﬁve applications of SS cream and
one of placebo. One study35 used different doses of SS cream;
only the results for the maximum dose (0.2 g) are presented.
Patients might have had less severe PE than those in some other
studies because the inclusion criterion was an IELT shorter than
3 minutes (combined with low partner satisfaction in one study).
Adverse effects included a mild burning sensation in 15% of
patients (the two studies) and mild pain in 0.04% to 4% of
patients (Table 4).Summary
The included studies evaluated the effectiveness of acupunc-
ture, Chinese herbal medicine, Ayurvedic herbal medicine, and
topical SS cream in improving IELT and other outcomes.
Overall risk of bias was unclear in all studies because of unclear
allocation concealment and/or blinding. Studies were clinically
heterogeneous and stopwatch-measured IELT was reported in
only 5 of 10 studies. Acupuncture increased IELT over placebo
(one study; MD ¼ 0.55 minute, P ¼ .001). Ayurvedic herbal
medicine increased IELT over placebo (one study; MD ¼ 0.80
minute, P ¼ .001). Topical SS cream improved IELT over
placebo in two crossover studies (MD ¼ 8.60 minutes,
P < .001), although inclusion criteria were broad (IELT < 3
minutes), and there were mild irritant effects in some patients.
SSRIs were more effective on IELT than Chinese herbal medi-
cine (three studies; MD ¼ 1.01 minutes, P ¼ .02). However,
combination treatment with Chinese medicine plus SSRIs
improved IELT over SSRIs alone (two studies; MD ¼ 1.92
minutes, P < .00001) or Chinese medicine alone (two studies;MD ¼ 2.52 minutes, P < .00001). Adverse effects were not
consistently assessed but where reported were generally mild.
There were sparse data on the potential for drug interactions.DISCUSSION
Our systematic review is (to our knowledge) the ﬁrst to
evaluate CAM for PE. All studies were classed as having an
overall unclear risk of bias because of limited reporting. Blinding
of participants and personnel was difﬁcult in many studies
because of the nature of the interventions, although a few studies
used placebo. However, because most studies included an active
control group (eg, drug treatment), any placebo effect might be
expected to occur in the two groups. It was not possible to
conduct a formal test for publication bias or produce funnel plots
because of the small number of studies in each analysis. How-
ever, all but three studies were conducted in single centers,31,32,34
and single-center trials tend to show larger treatment effects than
multicenter trials,40 possibly because of a lower likelihood of
publication if the result is negative (publication bias), lower
methodologic quality, and/or more selected patients.23
Regarding outcomes, 9 of 10 included studies assessed IELT
but only ﬁve reported on stopwatch-measured IELT. Because
IELT tends to be positively skewed, it has been suggested that
studies should report geometric (rather than arithmetic) mean
IELT.41 None of the included studies reported geometric mean
IELT, although two studies used the Mann-Whitney U-test for
between-group differences because of non-normal distribution of
data.26,29 Additional outcomes included PEDT, CIPE-5, and
IIEF scores. Although it is important that clinical studies assess
non-IELT outcomes in addition to IELT,42 there is a need for
greater agreement on which measurements are most robust.
Duration of the interventions was 2 to 8 weeks in all studies
(or one to ﬁve applications for SS cream). Only one study
(of Chinese medicine) provided follow-up data beyond the end
of treatment and reported that differences remained signiﬁcant
1 month after treatment ended. For most interventions, it was
not clear how long the effects might last or whether repeat
treatments were effective. This is an issue for all PE treatments.
An interesting point relates to the nature of CAM therapies. In
clinical practice, many CAM therapies involve a holistic
approach based on the patient’s overall pattern of health. It canSex Med 2017;5:e1ee18
CAM for Management of Premature Ejaculation e15be difﬁcult to determine how much of the treatment effect is due
to the speciﬁc treatment (acupuncture, herbs) and how much is
due to the patient-therapist interaction and other aspects
(eg, lifestyle advice). Some researchers believe the patient-
therapist interaction and other aspects of treatment should be
controlled for, whereas others argue that they are a valid element
of treatment.43e45 A related issue is whether CAM therapies are
individualized to the patient (eg, in clinical practice, two patients
with PE might receive different herbal remedies or acupuncture
points depending on their overall symptom picture).43,44 All
studies included in this review used a standardized treatment
across patients within a study (same set of acupuncture points or
same Chinese herbal preparation), although treatments varied
among studies. Although standardized treatment protocols
increase reproducibility, effectiveness of CAM therapies could be
compromised by this approach.
None of the included therapies are commonly provided for PE
by Western government health services. This has implications for
access and use of these therapies. Acupuncture, Chinese medi-
cine, and Ayurvedic medicine might be available from private
practitioners, whereas SS cream currently has limited availability
outside Korea. Pragmatically, because there are so many CAM
therapies available, it seems unlikely that they will all undergo
further evaluation in large-scale studies. Therefore, it might be
reasonable to summarize that the CAM therapies reviewed here
have some (although limited) evidence for effectiveness in
treating PE, and that they might provide another option for
patients who favor a mind-body approach or who wish to avoid
long-term pharmacologic treatment. It would need to be borne
in mind that the effectiveness evidence is not conclusive, and care
would need to be taken to monitor for adverse effects and to
consider the potential for herb-drug interactions.
Regarding further research, it would be useful to see further
RCTs in a Western setting for any of the included treatments,
because all had some (limited) evidence of effectiveness in PE. It
would be useful to conduct comparisons against placebo, no
treatment, existing therapies (drug or behavioral treatment), and
combination treatment. To increase consistency and facilitate
meta-analyses, future studies should recruit men meeting the
ISSM deﬁnition of PE, measure stopwatch-assessed IELT, and
report additional outcomes using validated instruments.
Additional areas for further study could include optimum
duration of therapy and how effects might best be maintained in
the long term.
CONCLUSIONS
There is preliminary evidence for effectiveness of some CAM
therapies in PE. However, results are based on clinically
heterogeneous, mostly single-center studies of unclear quality.
Acupuncture, Ayurvedic medicine, and SS cream improved
IELT and other outcomes over placebo based on limited data.
Chinese herbal medicine was not as effective as SSRIs, whereas
combination treatment with Chinese medicine plus SSRIsSex Med 2017;5:e1ee18improved outcomes over either therapy alone. Adverse effects
were not consistently assessed, although where reported they
were generally mild, and there were sparse data on the potential
for drug interactions. Further well-conducted RCTs of all
treatments would be valuable.
ACKNOWLEDGMENTS
We thank Shijie Ren and Ziyi Lin for translation of articles
and Naila Dracup for updating literature searches.
Corresponding Author: Katy Cooper, PhD, ScHARR,
University of Shefﬁeld, Regent Court, 30 Regent Street, Shefﬁeld
S1 4DA, UK. Tel: þ44-0-114-222-0773; E-mail: k.l.cooper@
shefﬁeld.ac.uk
Conﬂicts of Interest: Authors report no conﬂicts of interest.
Funding: This work was funded by the UK National Institute for
Health Research Health Technology Assessment Programme
(project number 13-12).STATEMENT OF AUTHORSHIP
Category 1
(a) Conception and Design
Katy Cooper; Marrissa Martyn-St James; Eva Kaltenthaler;
Kath Dickinson; Anna Cantrell(b) Acquisition of Data
Katy Cooper; Marrissa Martyn-St James; Kath Dickinson;
Anna Cantrell(c) Analysis and Interpretation of Data
Katy Cooper; Marrissa Martyn-St James; Eva Kaltenthaler;
Shijie Ren; Kevan Wylie; Leila Frodsham; Catherine HoodCategory 2
(a) Drafting the Article
Katy Cooper(b) Revising It for Intellectual Content
Katy Cooper; Marrissa Martyn-St James; Eva Kaltenthaler;
Kath Dickinson; Anna Cantrell; Shijie Ren; Kevan Wylie;
Leila Frodsham; Catherine HoodCategory 3
(a) Final Approval of the Completed Article
Katy Cooper; Marrissa Martyn-St James; Eva Kaltenthaler;
Kath Dickinson; Anna Cantrell; Shijie Ren; Kevan Wylie;
Leila Frodsham; Catherine HoodREFERENCES
1. Serefoglu EC, McMahon CG,Waldinger MD, et al. An evidence-
based uniﬁed deﬁnition of lifelong and acquired premature
ejaculation: report of the Second International Society for
Sexual Medicine Ad Hoc Committee for the Deﬁnition of
Premature Ejaculation. Sex Med 2014;2:41-59.
2. American Psychiatric Association. Diagnostic and statistical
manual of mental disorders. 5th ed. text rev. Washington, DC:
American Psychiatric Association; 2013.
e16 Cooper et al3. Laumann EO, Nicolosi A, Glasser DB, et al. Sexual problems
among women and men aged 40e80 y: prevalence and
correlates identiﬁed in the Global Study of Sexual Attitudes
and Behaviors. Int J Impot Res 2005;17:39-57.
4. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the
United States: prevalence and predictors. JAMA 1999;
281:537-544.
5. Porst H, Montorsi F, Rosen RC, et al. The Premature Ejacu-
lation Prevalence and Attitudes (PEPA) survey: prevalence,
comorbidities, and professional help-seeking. Eur Urol 2013;
51:816-823.
6. Althof SE, McMahon CG, Waldinger MD, et al. An update of
the International Society of Sexual Medicine’s guidelines for
the diagnosis and treatment of premature ejaculation (PE).
Sex Med 2014;11:1392-1422.
7. Rowland DL, Patrick DL, Rothman M, et al. The psychological
burden of premature ejaculation. J Urol 2007;177:1065-1070.
8. Byers ES, Grenier G. Premature or rapid ejaculation: hetero-
sexual couples’ perceptions of men’s ejaculatory behavior.
Arch Sex Behav 2003;32:261-270.
9. Richardson D, Goldmeier D, Green J, et al. Recommendations
for the management of premature ejaculation: BASHH Special
Interest Group for Sexual Dysfunction. Int J STD AIDS 2006;
17:1-6.
10. Hatzimouratidis K, Eardley I, Giuliano F, et al. Guidelines on
male sexual dysfunction: erectile dysfunction and premature
ejaculation. European Association of Urology. Eur Urol 2010;
57:804-814.
11. Melnik T, Althof S, Atallah AN, et al. Psychosocial in-
terventions for premature ejaculation. Cochrane Database
Syst Rev 2011;(8):CD008195.
12. Cooper K, Martyn-St James M, Kaltenthaler E, et al.
Behavioral therapies for management of premature ejacula-
tion: a systematic review. Sex Med 2015;3:174-188.
13. Cooper K, Martyn-St James M, Kaltenthaler E, et al.
Interventions to treat premature ejaculation: a systematic
review short report. Health Technol Assess 2015;19:1-180.
14. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items
for systematic reviews and meta-analyses: the PRISMA
statement. Ann Intern Med 2009;151:264-269, W64.
15. Wieland LS, Manheimer E, Berman BM. Development and
classiﬁcation of an operational deﬁnition of complementary
and alternative medicine for the Cochrane collaboration. Altern
Ther Health Med 2011;17:50-59.
16. Patrick DL, Giuliano F, Ho KF, et al. The Premature Ejaculation
Proﬁle: validation of self-reported outcome measures for
research and practice. BJU Int 2009;103:358-364.
17. Althof S, Rosen R, Symonds T, et al. Development and vali-
dation of a new questionnaire to assess sexual satisfaction,
control, and distress associated with premature ejaculation.
J Sex Med 2006;3:465-475.
18. Symonds T, Perelman MA, Althof S, et al. Development and
validation of a premature ejaculation diagnostic tool. Eur Urol
2007;52:565-573.19. Arafa M, Shamloul R. Development and evaluation of the
Arabic Index of Premature Ejaculation (AIPE). J Sex Med
2007;4:1750-1756.
20. Yuan YM, Xin ZC, Jiang H, et al. Sexual function of premature
ejaculation patients assayed with Chinese Index of Premature
Ejaculation. Asian J Androl 2004;6:121-126.
21. Rosen RC, Riley A, Wagner G, et al. The International Index of
Erectile Function (IIEF): a multidimensional scale for assess-
ment of erectile dysfunction. Urology 1997;49:822-830.
22. Cochrane Collaboration Review Manager (RevMan). London:
Cochrane Collaboration; 2012.
23. Cochrane Collaboration. Cochrane handbook for systematic
reviews of interventions version 5.1.0. London: Cochrane
Collaboration; 2011.
24. Higgins JPT, Altman DG, Sterne JAC; on behalf of the
Cochrane Statistical Methods Group and the Cochrane Bias
Methods Group. Assessing risk of bias in included studies. In:
Higgins JPT, ed. Cochrane handbook for systematic reviews of
interventions version 5.1.0. London: Cochrane Collaboration;
2011. Available at: www.cochrane-handbook.org. Accessed
July 18, 2016.
25. Wright CC, Sim J. Intention-to-treat approach to data from
randomized controlled trials: a sensitivity analysis. J Clin
Epidemiol 2003;56:833-842.
26. Sunay D, Sunay M, Aydogmus Y, et al. Acupuncture versus
paroxetine for the treatment of premature ejaculation: a ran-
domized, placebo-controlled clinical trial. Eur Urol 2011;
59:765-771.
27. Chen ZX. Control study on acupuncture and medication for
treatment of primary simple premature ejaculation. Zhongguo
Zhen Jiu 2009;29:13-15.
28. Li JX, Lu QG. Efﬁcacy of Qilin pills combined with sertraline in
the treatment of secondary non-consolidated kidney qi
premature ejaculation. Zhong Hua Nan Ke Xue 2015;
21:443-446.
29. Xu G, Jiang HW, Fang J, et al. An improved dosage regimen of
sertraline hydrochloride in the treatment for premature ejac-
ulation: an 8-week, single-blind, randomized controlled study
followed by a 4-week, open-label extension study. J Clin
Pharm Ther 2014;39:84-90.
30. Xu JX, Gao G, Xu N, et al. Yimusake alone or combined with
trazodone hydrochloride for primary premature ejaculation.
Zhonghua Nan Ke Xue 2012;18:376-378.
31. Sun Z, Wang Y, Chen L, et al. Clinical study on treatment of
premature ejaculation with ﬂuoxetine hydrochloride and
tamsulosin. Chinese J Androl 2010;24:43-45.
32. Song GH, Halmurat U, Geng JC, et al. Clinical study on the
treatment of premature ejaculation by Uighur medicine
gu-jing-mai-si-ha tablet. Chin J Integr Med 2007;13:185-189.
33. Kulkarni PV, Chandola H. Evaluation of stambhanakaraka yoga
and counseling in the management of shukragata vata
(premature ejaculation). Ayu 2013;34:42-48.
34. Choi HK, Jung GW, Moon KH, et al. Clinical study of SS-cream
in patients with lifelong premature ejaculation. Urology 2000;
55:257-261.Sex Med 2017;5:e1ee18
CAM for Management of Premature Ejaculation e1735. Choi HK, Xin ZC, Choi YD, et al. Safety and efﬁcacy study with
various doses of SS-cream in patients with premature ejacu-
lation in a double-blind, randomized, placebo controlled clinical
study. Int J Impot Res 1999;11:261-264.
36. Pei JT, Shi ZH. An effective combined therapy for
simple premature ejaculation. Zhonghua Nan Ke Xue 2008;
14:731-733.
37. Zhang FB, Tian Y, Du LD. Xuanju compound capsule
combined with erogenous focus exercise is effective for
premature ejaculation. Zhonghua Nan Ke Xue 2006;
12:1139-1140.
38. Dhikav V, Karmarkar G, Gupta M, et al. Yoga in premature
ejaculation: a comparative trial with ﬂuoxetine. J Sex Med
2007;4:1726-1732.
39. Mamidi P, Gupta K. Efﬁcacy of certain yogic and naturopathic
procedures in premature ejaculation: a pilot study. Int J Yoga
2013;6:118-122.
40. Dechartres A, Boutron I, Trinquart L, et al. Single-center trials
show larger treatment effects than multicenter trials: evidence
from a meta-epidemiologic study. Ann Intern Med 2011;
155:39-51.
41. Waldinger MD, Zwinderman AH, Olivier B, et al. Geometric
mean IELTand premature ejaculation: appropriate statistics to
avoid overestimation of treatment efﬁcacy. J Sex Med 2008;
5:492-499.
42. McMahon CG. Ejaculatory latency vs. patient-reported
outcomes (PROs) as study end points in premature ejacula-
tion clinical trials. Eur Urol 2007;52:321-323.
43. Fonnebo V, Grimsgaard S, Walach H, et al. Researching
complementary and alternative treatments—the gate-
keepers are not at home. BMC Med Res Methodol 2007;
7:7.
44. MacPherson H, Sherman K, Hammerschlag R, et al. The
clinical evaluation of traditional East Asian systems of medi-
cine. Clin Acu Orient Med 2002;3:16-19.
45. Relton C, O’Cathain A, Thomas KJ. ‘Homeopathy’: untangling
the debate. Homeopathy 2008;97:152-155.SUPPLEMENTARY DATA
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.esxm.2016.08.002.APPENDIX 1. MEDLINE SEARCH STRATEGY
Medline search strategySex1. exp Ejaculation/
2. exp Premature Ejaculation/
3. (premature$ adj3 ejaculat$).ti,ab.
4. (early adj3 ejaculat$).ti,ab.
5. (rapid adj3 ejaculat$).ti,ab.Med 2017;5:e1ee186. (rapid adj3 climax$).ti,ab.
7. (premature$ adj3 climax$).ti,ab.
8. (ejaculat$ adj3 pr?ecox).ti,ab.
9. or/1-8.
Filter 1: Randomized Controlled Trials10. Randomized Controlled Trials as Topic/
11. randomized controlled trial/
12. Random Allocation/
13. Double Blind Method/
14. Single Blind Method/
15. clinical trial/
16. clinical trial, phase i.pt.
17. clinical trial, phase ii.pt.
18. clinical trial, phase iii.pt.
19. clinical trial, phase iv.pt.
20. controlled clinical trial.pt.
21. randomized controlled trial.pt.
22. multicenter study.pt.
23. clinical trial.pt.
24. exp Clinical Trials as topic/
25. or/10-24
26. (clinical adj trial$).tw.
27. ((singl$ or doubl$ or treb$ or tripl$) adj (blind$3 or
mask$3)).tw.
28. PLACEBOS/
29. placebo$.tw.
30. randomly allocated.tw.
31. (allocated adj2 random$).tw.
32. 26 or 27 or 28 or 29 or 30 or 31
33. 25 or 32
34. case report.tw.
35. letter/
36. historical article/
37. 34 or 35 or 36
38. 33 not 37
Filter 2: Reviews10. review.ab.
11. review.pt.
12. meta-analysis.ab.
e18 Cooper et al13. meta-analysis.pt.
14. meta-analysis.ti.
15. or/10-14
16. letter.pt.
17. comment.pt.
18. editorial.pt.
19. or/16-1820. 15 not 19
Filter 3: Guidelines10. guideline.pt.
11. practice guideline.pt.
12. exp Guideline/
13. health planning guidelines/
14. 10 or 11 or 12 or 13Sex Med 2017;5:e1ee18
